Brokerages Set argenex SE (NASDAQ:ARGX) Price Target at $986.78

argenex SE (NASDAQ:ARGX) has earned a consensus rating of “Moderate Buy” from the twenty-four research firms that are covering the company, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation, eighteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $986.7778.

Several equities analysts recently weighed in on ARGX shares. Morgan Stanley increased their price target on shares of argenex from $1,070.00 to $1,110.00 and gave the company an “overweight” rating in a research report on Thursday, December 4th. Citigroup decreased their price target on shares of argenex from $1,124.00 to $1,091.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Wall Street Zen downgraded argenex from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Stifel Nicolaus raised their target price on argenex from $1,028.00 to $1,248.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Finally, DZ Bank upgraded argenex to a “strong-buy” rating in a research note on Friday, December 19th.

Hedge Funds Weigh In On argenex

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ARGX. Abound Wealth Management increased its stake in shares of argenex by 3,200.0% in the fourth quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after purchasing an additional 32 shares in the last quarter. Sound Income Strategies LLC purchased a new position in argenex in the 4th quarter valued at approximately $28,000. Ameriflex Group Inc. bought a new stake in argenex during the 3rd quarter valued at $32,000. Aventura Private Wealth LLC purchased a new stake in shares of argenex during the fourth quarter worth $38,000. Finally, Sunbelt Securities Inc. bought a new position in shares of argenex in the third quarter worth $36,000. Institutional investors own 60.32% of the company’s stock.

argenex Price Performance

Shares of NASDAQ:ARGX opened at $818.46 on Friday. argenex has a 1 year low of $510.05 and a 1 year high of $934.62. The company has a market capitalization of $50.65 billion, a PE ratio of 35.14, a price-to-earnings-growth ratio of 0.73 and a beta of 0.37. The business has a fifty day moving average price of $829.64 and a two-hundred day moving average price of $810.13.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.